Mast Therapeutics

We are a biopharmaceutical company developing novel, clinical-stage therapies for serious or life-threatening diseases with significant unmet needs. We have built our product pipeline through the strategic acquisition of privately-held companies with clinical-stage assets and we currently are focused on developing new therapies for sickle cell disease, a chronic, genetic disorder classified as a rare, or orphan, disease in the United States and European Union, and for heart failure, a condition with a high unmet need for innovative treatment options.
Type
Public
HQ
San Diego, US
Founded
1995
Size (employees)
6 (est)-78%
Mast Therapeutics was founded in 1995 and is headquartered in San Diego, US

Mast Therapeutics Office Locations

Mast Therapeutics has an office in San Diego
San Diego, US (HQ)
500 3611 Valley Centre Dr

Mast Therapeutics Metrics

Mast Therapeutics Financial Metrics

Revenue (2016)

$128 k

Net income (2016)

($36.1 m)

Market capitalization (21-Mar-2017)

$26.9 m

Closing share price (21-Mar-2017)

$0.1

Cash (31-Dec-2016)

$8.5 m
Mast Therapeutics's current market capitalization is $26.9 m.
Mast Therapeutics's revenue was reported to be $128 k in FY, 2016
FY, 2013Y, 2014Y, 2015FY, 2016

Revenue

$128 k

Revenue growth, %

(100%)

R&D expense

$12.9 m

General and administrative expense

$8.5 m

Operating expense total

$21.5 m$29.3 m$39.4 m$36.6 m

EBIT

($21.5 m)($29.3 m)($39.4 m)($36.5 m)

EBIT margin, %

(28481%)

Interest expense

$603 k$2.1 m

Interest income

$60.3 k$69 k$130 k$122 k

Pre tax profit

($38.5 m)

Income tax expense

$2.4 m

Net Income

($21.5 m)($28.7 m)($39.8 m)($36.1 m)
FY, 2013FY, 2014FY, 2015FY, 2016

Cash

$25.7 m$35.8 m$23.1 m$8.5 m

Accounts Receivable

Inventories

$1.1 m$1.1 m$1.3 m$903 k

Current Assets

$45.5 m$58.4 m$42.3 m$12.2 m

PP&E

$105.7 k$188 k$226 k$99 k

Goodwill

$3 m$3 m$3 m$3 m

Total Assets

$55.2 m$70.5 m$54.2 m$17.9 m

Accounts Payable

$963.9 k$1.4 m$2.6 m$626 k

Current Liabilities

$4.8 m$8.4 m$23.2 m$4.9 m

Additional Paid-in Capital

$254.2 m$293.7 m$298.7 m$320.6 m

Retained Earnings

($235.1 m)($275 m)($311.1 m)

Total Equity

$47.8 m$58.7 m$23.9 m$9.8 m

Financial Leverage

1.2 x1.2 x2.3 x1.8 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

($21.5 m)($28.7 m)($39.8 m)($36.1 m)

Depreciation and Amortization

$39.5 k$85 k$146 k$99 k

Accounts Receivable

Inventories

Accounts Payable

$2.5 m$2.5 m$1.2 m

Cash From Operating Activities

($17.8 m)($24.6 m)($32.9 m)($37.3 m)

Purchases of PP&E

($46.8 k)($147 k)($165 k)($8 k)

Cash From Investing Activities

($4.8 m)$481 k$3.4 m$15.2 m

Cash From Financing Activities

$25.7 m$34.3 m$16.8 m$7.6 m

Mast Therapeutics Market Value History

Mast Therapeutics Online Presence

Mast Therapeutics Company Life

You may also be interested in